FGF-23 in patients with end-stage renal disease on hemodialysis
- 1 May 2004
- journal article
- Published by Elsevier in Kidney International
- Vol. 65 (5), 1943-1946
- https://doi.org/10.1111/j.1523-1755.2004.00604.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/OsteomalaciaJournal of Clinical Endocrinology & Metabolism, 2002
- Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23Kidney International, 2001
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences, 2001
- The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate WastingJournal of Clinical Endocrinology & Metabolism, 2001
- Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23Nature Genetics, 2000
- Control of serum phosphate in patients with renal failure--new approaches.Nephrology Dialysis Transplantation, 1998
- A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic ricketsNature Genetics, 1995
- Tumor-Induced Osteomalacia -- Unveiling a New HormoneNew England Journal of Medicine, 1994
- Serum Parathyroid Hormone in X-Linked HypophosphatemiaScience, 1971